The evolution of single-use duodenoscope utilization at a large-volume endoscopic retrograde cholangiopancreatography tertiary care center

iGIE Pub Date : 2025-06-01 DOI:10.1016/j.igie.2025.03.014
Yervant Ichkhanian MD , Hashem N. Albunni MBBS , Aditya Gutta MD , James L. Watkins MD , Evan L. Fogel MD , Jeffrey J. Easler MD , Nasir Saleem MD , Mark A. Gromski MD
{"title":"The evolution of single-use duodenoscope utilization at a large-volume endoscopic retrograde cholangiopancreatography tertiary care center","authors":"Yervant Ichkhanian MD ,&nbsp;Hashem N. Albunni MBBS ,&nbsp;Aditya Gutta MD ,&nbsp;James L. Watkins MD ,&nbsp;Evan L. Fogel MD ,&nbsp;Jeffrey J. Easler MD ,&nbsp;Nasir Saleem MD ,&nbsp;Mark A. Gromski MD","doi":"10.1016/j.igie.2025.03.014","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and Aims</h3><div>Previous studies have shown promising outcomes with single-use duodenoscopes, often examining only 1 version. The aim of this study was to evaluate the long-term outcomes across multiple models at a large referral center.</div></div><div><h3>Methods</h3><div>Endoscopic retrograde cholangiopancreatography (ERCP) cases (July 2020-September 2023) were retrospectively reviewed to assess technical success, defined as successful cannulation without switching devices. A 3-tier system guided the use of single-use duodenoscopes: recommended for drug-resistant cases (Tier 1), considered for immunosuppressed patients (Tier 2), and discouraged in routine cases (Tier 3).</div></div><div><h3>Results</h3><div>Of 8375 ERCPs, 267 (3.2%) involved single-use duodenoscopes (Tier 1, 25%; Tier 2, 54%; and Tier 3, 21%). The majority focused on the biliary system (91%), with 9% targeting the pancreatic duct. Technical success was achieved in 94%. Technical failures were primarily due to poor imaging (53%) and inadequate maneuverability (47%). Adverse events were reported in 3% of cases. A gradual increase was observed in ERCPs using single-use duodenoscopes, from 2.6% in 2020 to 4.7% in 2023, alongside a notable decrease in Tier 3 usage from 29% to 14%. The use for native papillae rose from 9.8% to 21%, while pancreatic duct interventions dropped significantly from 15% to 4.8%. Junior faculty performed 84% of procedures, reporting greater satisfaction than senior faculty. Improvements in scope stiffness, image stability, and elevator functionality were noted with newer iterations.</div></div><div><h3>Conclusions</h3><div>This study offers real-world evidence of successful single-use duodenoscope integration into a high-volume practice, with growing use and increased endoscopist satisfaction over time.</div></div>","PeriodicalId":100652,"journal":{"name":"iGIE","volume":"4 2","pages":"Pages 139-148"},"PeriodicalIF":0.0000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"iGIE","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S294970862500041X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background and Aims

Previous studies have shown promising outcomes with single-use duodenoscopes, often examining only 1 version. The aim of this study was to evaluate the long-term outcomes across multiple models at a large referral center.

Methods

Endoscopic retrograde cholangiopancreatography (ERCP) cases (July 2020-September 2023) were retrospectively reviewed to assess technical success, defined as successful cannulation without switching devices. A 3-tier system guided the use of single-use duodenoscopes: recommended for drug-resistant cases (Tier 1), considered for immunosuppressed patients (Tier 2), and discouraged in routine cases (Tier 3).

Results

Of 8375 ERCPs, 267 (3.2%) involved single-use duodenoscopes (Tier 1, 25%; Tier 2, 54%; and Tier 3, 21%). The majority focused on the biliary system (91%), with 9% targeting the pancreatic duct. Technical success was achieved in 94%. Technical failures were primarily due to poor imaging (53%) and inadequate maneuverability (47%). Adverse events were reported in 3% of cases. A gradual increase was observed in ERCPs using single-use duodenoscopes, from 2.6% in 2020 to 4.7% in 2023, alongside a notable decrease in Tier 3 usage from 29% to 14%. The use for native papillae rose from 9.8% to 21%, while pancreatic duct interventions dropped significantly from 15% to 4.8%. Junior faculty performed 84% of procedures, reporting greater satisfaction than senior faculty. Improvements in scope stiffness, image stability, and elevator functionality were noted with newer iterations.

Conclusions

This study offers real-world evidence of successful single-use duodenoscope integration into a high-volume practice, with growing use and increased endoscopist satisfaction over time.
大容量内窥镜逆行胆管造影三级保健中心单次使用十二指肠镜的演变
背景和目的以前的研究表明,使用一次性十二指肠镜通常只检查1个版本,结果很有希望。本研究的目的是评估大型转诊中心的多种模式的长期结果。方法回顾性分析内镜下逆行胆管造影(ERCP)病例(2020年7月至2023年9月),评估技术成功,定义为成功插管,无需切换装置。一个三层系统指导了一次性十二指肠镜的使用:推荐用于耐药病例(第1层),考虑用于免疫抑制患者(第2层),不鼓励用于常规病例(第3层)。在8375例ercp中,267例(3.2%)涉及一次性十二指肠镜(Tier 1, 25%;2级,54%;第三级占21%)。大多数集中在胆道系统(91%),9%针对胰管。技术成功率达94%。技术故障主要是由于成像不良(53%)和机动性不足(47%)。3%的病例报告了不良事件。使用一次性十二指肠镜的ercp逐渐增加,从2020年的2.6%增加到2023年的4.7%,同时三级使用率从29%显著下降到14%。原生乳头的使用从9.8%上升到21%,而胰管干预从15%显著下降到4.8%。初级教师执行了84%的程序,报告满意度高于高级教师。在范围刚度,图像稳定性和电梯功能的改进,注意到较新的迭代。结论:本研究提供了真实世界的证据,证明了一次性十二指肠镜与大容量实践的成功结合,随着时间的推移,使用越来越多,内窥镜医师的满意度也越来越高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信